These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
    Author: Shouval R, Livneh A, Ben-Zvi I.
    Journal: Harefuah; 2015 Nov; 154(11):716-9, 741. PubMed ID: 26821505.
    Abstract:
    Familial Mediterranean Fever (FMF) is a common genetic auto-inflammatory disease in the Middle Eastern population. Colchicine is the only proven treatment for the prevention of FMF attacks and reactive amyloidosis. However, 5-10% of FMF patients do not respond to colchicine, and an additional 5% are intolerant to it. Progress in the understanding of FMF and the recognition of the central role of IL-1 in its pathophysiology has led to the introduction of IL-1 inhibitors in FMF patients who are unresponsive to colchicine. In this paperwe review the clinical experience gained with IL-1 inhibitors in FMF. Overall, it appears that IL-1 inhibitors are safe and may serve as an alternative in FMF patients resistant to colchicine.
    [Abstract] [Full Text] [Related] [New Search]